FDA nixes melanoma use for PegIntron

Despite an advisory panel's recommendation, the FDA has declined to approve a new use for Schering-Plough's PegIntron, saying that it has "outstanding concerns" about a melanoma indication for the drug. Report

Suggested Articles

After years of having first-line liver cancer market to itself, Bayer’s Nexavar is getting major competition from Roche's Tecentriq.

Most of the recent enthusiasm around AbbVie’s new drugs has centered on Skyrizi and Rinvoq, but elagolix wants a piece of the spotlight, too.

During David Loew's tenure, Sanofi Pasteur bought Protein Sciences, whose recombinant technology is being applied to a COVID-19 vaccine.